This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!